8-K: Amedisys Reports Strong Adjusted Q2 2025 Results Amidst Rising Merger Costs and Regulatory Scrutiny

Amedisys, Inc. announced increased adjusted revenue and profitability for the second quarter of 2025, despite a GAAP net income decline driven by significant merger-related expenses and ongoing regulatory challenges to its proposed acquisition by UnitedHealth Group.

Summary

• Net service revenue increased by $30.7 million to $621.9 million for the three-month period ended June 30, 2025, compared to $591.2 million in 2024.
• GAAP net income attributable to Amedisys, Inc. for Q2 2025 was $28.1 million, down from $32.3 million in Q2 2024, inclusive of $26.3 million in merger-related expenses.
• Adjusted EBITDA for Q2 2025 increased to $80.8 million, up from $73.2 million in Q2 2024.
• Adjusted net income attributable to Amedisys, Inc. for Q2 2025 was $51.4 million, compared to $43.5 million in Q2 2024.
• Adjusted diluted earnings per share for Q2 2025 were $1.54, an increase from $1.32 in Q2 2024.
• For the six-month period ended June 30, 2025, net service revenue rose to $1,216.6 million from $1,162.6 million in 2024.
• Year-to-date GAAP net income was $89.1 million, up from $46.7 million in 2024, benefiting from a $48.1 million gain on an equity method investment.
• Year-to-date adjusted EBITDA reached $149.6 million, an increase from $133.0 million in 2024.
• Days revenue outstanding (DSO) improved to 40.9 days as of June 30, 2025, down from 52.1 days in the prior year.
• Free cash flow for Q2 2025 was $56.7 million, an increase from $42.3 million in Q2 2024.
• The company maintains a net leverage ratio of 0.1x and $508.0 million in revolver availability as of June 30, 2025.
• Home Health segment reported a 6% increase in same-store admissions and a 0.7% increase in Medicare revenue per episode to $3,058.
• Hospice segment saw a 0.4% increase in same-store admissions and a 1.3% increase in average daily census (ADC), with revenue per day up 4.1% to $179.96.
• General and administrative expenses as a percentage of revenue decreased by 150 basis points year-over-year to 31.6% in Q2 2025.
• Amedisys achieved a 4.16 Quality of Patient Care (QPC) Star average in the July 2025 HHC Final release, with 89% of providers at 4+ Stars.
• Patient Satisfaction Star rating was 3.69 in the July 2025 Final release, performing 1% above the industry average.

Sentiment

Score: 6

Explanation: The company demonstrated strong operational performance with growth in adjusted revenue and profitability, and improved cash flow. However, the significant merger-related expenses impacting GAAP net income, the proposed future reimbursement cut for Home Health, and the ongoing uncertainty and litigation surrounding the UnitedHealth Group merger introduce considerable headwinds and risk, balancing the positive operational results.

Positives

• Net service revenue increased by $30.7 million for Q2 2025 and $54.0 million for the six-month period ended June 30, 2025, demonstrating continued top-line growth.
• Adjusted EBITDA grew to $80.8 million in Q2 2025 and $149.6 million year-to-date, indicating strong operational profitability excluding certain items.
• Adjusted net income and diluted EPS showed significant increases for both the quarter and year-to-date periods, reflecting improved underlying earnings power.
• Days revenue outstanding (DSO) improved substantially to 40.9 days, indicating efficient accounts receivable collection.
• Free cash flow increased to $56.7 million in Q2 2025, providing strong liquidity.
• The company maintains a very low net leverage ratio of 0.1x and substantial revolver availability of $508.0 million, indicating a strong financial position.
• Home Health and Hospice segments showed positive same-store volume and admission growth, along with increases in revenue per episode/day.
• General and administrative expenses as a percentage of revenue decreased, reflecting improved cost management.
• Amedisys maintains high quality scores, with a 4.16 QPC Star average and 89% of providers at 4+ Stars, demonstrating commitment to patient care excellence.

Negatives

• GAAP net income attributable to Amedisys, Inc. decreased to $28.1 million in Q2 2025 from $32.3 million in Q2 2024, primarily due to increased merger-related expenses.
• Merger-related expenses totaled $26.3 million in Q2 2025 and $43.0 million year-to-date, significantly impacting GAAP profitability.
• The proposed 2026 Home Health industry rule estimates a -6.4% decrease in reimbursement, effective January 1, 2026, posing a future revenue headwind.
• Home Health EBITDA margin decreased by 80 basis points, driven by wage increases and a shift in admissions mix.
• The company will not conduct a quarterly earnings call due to the pending merger, limiting direct management commentary and investor engagement.

Risks

• Disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier, or management and employee relationships.
• The occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on anticipated terms or by the end of the waiver period.
• The risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained, or are obtained subject to conditions that are not anticipated.
• The failure of the conditions to the proposed merger to be satisfied.
• The costs related to the proposed transaction.
• The diversion of management time on merger-related issues.
• The risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances.
• Reputational risk related to the proposed merger.
• The risk of litigation or regulatory action related to the proposed merger, including the action by the Department of Justice to block the merger.
• Changes in Medicare and other medical payment levels.
• Changes in payments and covered services by federal and state governments.
• Future cost containment initiatives undertaken by third-party payors.
• Changes in the episodic versus non-episodic mix of payors, the case mix of patients, and payment methodologies.
• Staffing shortages driven by the competitive labor market and the ability to attract and retain qualified personnel.
• Competition in the healthcare industry.
• Ability to maintain or establish new patient referral sources.
• Changes in or failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis.
• Changes in estimates and judgments associated with critical accounting policies.
• Ability to consistently provide high-quality care and keep patients and employees safe.
• Access to financing, ability to meet debt service requirements, and comply with covenants in debt agreements.
• Business disruptions due to natural or man-made disasters, climate change, acts of terrorism, widespread protests, or civil unrest.
• Ability to open care centers, acquire additional care centers, and integrate and operate these care centers effectively.
• Ability to realize the anticipated benefits of acquisitions, investments, and joint ventures.
• Ability to integrate, manage, and keep information systems secure.
• The impact of inflation and new or increased tariffs.
• Uncertainty around, and disruption from, new and emerging technologies, including the adoption and utilization of artificial intelligence ('AI') and generative AI.
• Changes in laws or developments with respect to any litigation relating to the Company.

Future Outlook

The company anticipates a +2.4% increase in hospice reimbursement effective October 1, 2025, based on the proposed 2026 Hospice industry rule. However, the proposed 2026 Home Health industry rule estimates a significant -6.4% decrease in reimbursement, effective January 1, 2026. The future of the proposed merger with UnitedHealth Group remains uncertain due to ongoing regulatory review and a Department of Justice action to block the transaction.

Management Comments

• In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the second quarter results.

Industry Context

Amedisys operates in the U.S. home health and hospice care industry, a sector facing evolving reimbursement policies and increasing demand for in-home services. The company's strong quality scores and patient satisfaction metrics position it favorably against industry averages. However, the industry is subject to significant regulatory changes, as evidenced by the proposed 2026 Home Health reimbursement decrease, which could impact future revenue across the sector. The pending merger with UnitedHealth Group, if approved, would significantly alter the competitive landscape and Amedisys's market position.

Comparison to Industry Standards

• Amedisys maintains a 4.16 Quality of Patient Care (QPC) Star average in the July 2025 HHC Final release, with 89% of its providers (representing 89% of care centers) at 4+ Stars and 40% at 4.5+ Stars. This performance is notably above the industry average QPC, which typically ranges between 3.8 and 3.9, and is competitive with top industry competitors.
• The company's Patient Satisfaction (PS) Star rating was 3.69 in the July 2025 Final release, performing 1% above the industry average PS, which typically ranges between 3.6 and 3.7. While above average, this is slightly below the performance of top industry competitors, which are typically around 3.8-3.9.
• The 2025 Hospice industry rule provided an estimated +2.9% increase in reimbursement (effective 10/1/24), and the 2025 Home Health industry rule provided an estimated +0.5% increase (effective 1/1/25), which are industry-wide adjustments impacting all comparable providers.
• The proposed 2026 Hospice industry rule suggests a +2.4% increase (effective 10/1/25), while the proposed 2026 Home Health industry rule indicates a significant -6.4% decrease (effective 1/1/26). These proposed changes represent a substantial headwind for the Home Health segment across the industry, potentially impacting Amedisys and its peers like LHC Group (now part of Optum/UnitedHealth Group) and Encompass Health's home health segment.

Legal Proceedings

• The Department of Justice has taken action to block the proposed merger with UnitedHealth Group.

Stakeholder Impact

• Shareholders face uncertainty regarding the outcome of the proposed merger, which could significantly impact share value depending on approval, termination, or conditions.
• Employees may experience disruption and uncertainty related to the pending merger, as well as potential impacts from staffing shortages and wage inflation.
• Patients are likely to continue receiving high-quality care, as indicated by the company's strong quality scores and patient satisfaction ratings.
• Payors and referral sources may be impacted by changes in payment levels and the potential integration of Amedisys into UnitedHealth Group's Optum division.

Next Steps

• Monitor the outcome of the proposed merger with UnitedHealth Group, including the Department of Justice's action to block the transaction.
• Observe the finalization of the 2026 Home Health and Hospice reimbursement rules and their impact on future revenue.

Key Dates

Recommendation

While Amedisys reported strong adjusted financial results, including revenue growth and improved cash flow, the ongoing uncertainty and significant costs associated with the pending merger with UnitedHealth Group, coupled with the Department of Justice's action to block the deal, create substantial risk. Additionally, the proposed 6.4% cut in Home Health reimbursement for 2026 presents a future headwind. Given the operational strength but considerable external risks and lack of clear resolution on the merger, a 'hold' recommendation is prudent for a seasoned investor awaiting clarity on these major strategic and regulatory factors.

Keywords

Home Health, Hospice, Healthcare Services, SEC Filing, Financial Results, Earnings, Merger, UnitedHealth Group, AMED, EBITDA, Revenue, Patient Care, Regulatory Risk, Medicare, Reimbursement